# EmendoBio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/emendobio

- Industry: Biotechnology
- Headquarters: New York, US
- Website: www.emendobio.com
- Total disclosed funding: $63M
- Latest round: Series B (Jan 15, 2020)
- Investors on record: 1

## About

EmendoBio Inc. is a biotechnology company specializing in advanced gene editing technologies, focusing on innovative CRISPR solutions to address complex genetic diseases effectively.Founded in 2015 and headquartered in New York, US, EmendoBio Inc. operates in the biotechnology sector, creating custom gene editing solutions. The company has engaged in four funding deals, with the latest being a Series B round in November 2020, where they raised USD 63.25 mn from Takeda Ventures, valuing the company at USD 205.458 mn.EmendoBio specializes in advanced gene editing technologies, primarily focusing on developing novel CRISPR solutions tailored to address complex genetic diseases. Their core offerings include custom-designed nucleases and optimized guide-RNAs that enhance gene editing precision and efficacy. The company's disease-first strategy prioritizes understanding genetic conditions before developing tailored therapies. EmendoBio caters to a diverse clientele, including research institutions, biotechnology firms, and pharmaceutical companies across North America, Europe, and Asia-Pacific.EmendoBio generates revenue through partnerships with biotechnology and pharmaceutical companies, facilitating collaborations for the development and commercialization of their CRISPR technologies. These partnerships typically involve B2B agreements for custom gene editing solutions tailored to client needs, with structured payments for services, milestone payments, and royalties on developed products. The focus on customized solutions suggests a tiered pricing strategy aligned with the complexity and scale of client projects.Following the acquisition of EmendoBio Inc. by AnGes, Inc. in November 2020, the company aims to leverage its innovative CRISPR technology to expand its market reach. Future plans include the design and launch of new gene editing products tailored to address evolving challenges in genetic therapy. EmendoBio is targeting expansion into markets in Asia-Pacific and Europe by 2023, utilizing the funds from their Series B round to support product development and market entry strategies.

## Funding rounds

- Series B, Jan 15, 2020, $63M — Takeda Ventures

## Investors

- Takeda Ventures (https://capitalatlas.ai/funds/takeda-ventures) — Series B